A composite risk analysis is to be considered for a patient at high risk of recurrence based on the following criteria: node-positive 1-3, ER/progesterone receptor <50%, grade 2/3, tumor size >2 cm, and Ki-67 >20%. This evidence concerns the gene ESR1 and neoplasm.